© 2002 by European Society of Cardiology
Copyright © 2002, European Society of Cardiology
Myocardial Na,K-ATPase: the molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure
aMedical Department B, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
bDepartment of Medicine and Cardiology A, Aarhus University Hospital, Aarhus, Denmark
cDivision of Cardiology, Northwestern Medical School, Chicago, IL, USA
* Corresponding author. Tel.: +45-35-452-628; fax: +45-35-452-648 kjeldsen{at}rh.dk
Congestive heart failure may be deemed the epidemic of cardiology in the 21st century in the industrialized part of the world. Although new therapies improving morbidity and mortality from chronic heart failure have emerged it is likely that there is a growing role for digoxin. Thus, digoxin treatment is known to control symptoms of congestive heart failure when added to standard therapy. In this setting, we review the prevailing knowledge of the Na,K-ATPase, the cellular receptor for the inotropic action of digitalis glycosides, in relation to the hemodynamic effect of digoxin. It is concluded that if improvement of hemodynamics is needed in congestive heart failure, this knowledge should be taken into account and in many cases digoxin should be added to standard therapy. Digoxin is still the only safe inotropic drug for oral use that improves hemodynamics. Digoxin should be used to heart failure patients in sinus rhythm when they after institution of mortality reducing treatment still have heart failure symptoms, and to patients intolerant to heart failure mortality reducing drugs. Digoxin should probably in heart failure patients with sinus rhythm be given in the lowest possible dose that relieves symptoms sufficiently.
KEYWORDS Heart failure; Hemodynamics; Ion pumps
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  X. T. Gan, X.-Q. Gong, J. Xue, J. V. Haist, D. Bai, and M. Karmazyn Sodium-hydrogen exchange inhibition attenuates glycoside-induced hypertrophy in rat ventricular myocytes Cardiovasc Res, September 13, 2009; (2009) cvp283v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Yang, D. G. Menter, C. Cartwright, D. Chan, S. Dixon, M. Suraokar, G. Mendoza, N. Llansa, and R. A. Newman Oleandrin-mediated inhibition of human tumor cell proliferation: Importance of Na,K-ATPase {alpha} subunits as drug targets Mol. Cancer Ther., August 1, 2009; 8(8): 2319 - 2328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Liu, X. Zhao, S. V. Pierre, and A. Askari Association of PI3K-Akt signaling pathway with digitalis-induced hypertrophy of cardiac myocytes Am J Physiol Cell Physiol, November 1, 2007; 293(5): C1489 - C1497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kometiani, L. Liu, and A. Askari Digitalis-Induced Signaling by Na+/K+-ATPase in Human Breast Cancer Cells Mol. Pharmacol., March 1, 2005; 67(3): 929 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. I. Dmitrieva and P. A. Doris Ouabain Is a Potent Promoter of Growth and Activator of ERK1/2 in Ouabain-resistant Rat Renal Epithelial Cells J. Biol. Chem., July 18, 2003; 278(30): 28160 - 28166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H.G Schwinger, H. Bundgaard, J. Muller-Ehmsen, and K. Kjeldsen The Na, K-ATPase in the failing human heart Cardiovasc Res, March 15, 2003; 57(4): 913 - 920. [Abstract] [Full Text] [PDF]
|
|